Biomea Fusion (BMEA) Corporate presentation summary

Strategic focus and pipeline

• Advancing two differentiated metabolic programs: icovamenib (oral menin inhibitor) and BMF-650 (oral GLP-1 receptor agonist), both targeting diabetes and obesity with large unmet needs.

• Retains full worldwide rights and is funded through major clinical milestones into 2Q 2027.

• Multiple Phase II readouts for both programs are anticipated over the next 12 months.

• Leadership team with experience and a clear execution plan.

• Cash runway supports key upcoming value inflection points.

Icovamenib: Mechanism and clinical results

• Icovamenib targets menin to restore beta cell mass and function, aiming to improve endogenous insulin production in both type 1 and type 2 diabetes.

• Preclinical and clinical data show increased C-peptide, reduced HbA1c, and improved beta cell function with favorable safety profile.

• In type 1 diabetes, a 52% mean increase in C-peptide and 0.6% mean reduction in HbA1c were observed after 12 weeks, with sustained C-peptide levels at 52 weeks.

• No evidence of systemic immune activation; safety profile comparable to placebo.

• Combination with GLP-1 RA showed synergistic effects on glycemic control and weight loss in preclinical models.

BMF-650: Next-generation oral GLP-1 RA

• Designed for improved tolerability, higher bioavailability, and scalable weight reduction.

• Preclinical studies show robust, dose-dependent weight loss in obese monkeys, with up to 15% reduction after 28 days.

• Demonstrated good potency, selectivity, and favorable pharmacokinetics compared to other oral GLP-1 RAs.

• Phase I study in healthy overweight/obese participants is ongoing, with Phase II initiation planned depending on results.

• Aims to address high discontinuation rates seen with current GLP-1 therapies due to GI side effects.